|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
Q1 FY2022
As of Jun 30, 2021
|
Q4 FY2021
As of Mar 31, 2021
|
Q3 FY2021
As of Dec 31, 2020
|
Q2 FY2021
As of Sep 30, 2020
|
Q1 FY2021
As of Jun 30, 2020
|
Q4 FY2020
As of Mar 31, 2020
|
Q3 FY2020
As of Dec 31, 2019
|
Q2 FY2020
As of Sep 30, 2019
|
Q1 FY2020
As of Jun 30, 2019
|
Q4 FY2019
As of Mar 31, 2019
|
Q3 FY2019
As of Dec 31, 2018
|
Q2 FY2019
As of Sep 30, 2018
|
Q1 FY2019
As of Jun 30, 2018
|
Q4 FY2018
As of Mar 31, 2018
|
Q3 FY2018
As of Dec 31, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term marketable securities | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Long-term marketable securities | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| In-process research and development | ||||||||||||||||||||
| Long-term deferred tax assets, net | ||||||||||||||||||||
| Other intangibles, net | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Contingent consideration | ||||||||||||||||||||
| Long-term deferred tax liabilities | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Common stock, $.01 par value 100,000 shares authorized; 48,418 and 48,258 shares issued as of September 31, 2022 and March 31, 2022, respectively 45,172 and 45,545 shares outstanding as of September 30, 2022 and March 31, 2022, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock at cost - 3,246 and 2,713 shares as of September 31, 2022 and March 31, 2022, respectively | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity |
Loading...
